Another approach combines zoledronate and IL-2 with engraftment of Vδ2-enriched PBMCs, used for solid cancers like colorectal and pancreatic cancers – although, results have been mixed – with some patients showing tumor progression despite localized reductions. This evidence concerns the gene IL2 and neoplasm.